PlainRecalls
FDA Drug Moderate Class II Terminated

Cefprozil for Oral Suspension USP, 250mg/5mL, packaged as a) 50 mL (when mixed) bottles (NDC 68180-402-01); b) 75 mL (when mixed) bottles (NDC 68180-402-02); and c) 100 mL (when mixed) bottles (NDC 68180-402-03); Rx only, Manufactured for: Lupin Pharmaceutical, Inc., Baltimore, MD 21202; Manufactured by: Lupin Limited, Mandideep 462 046, India.

Reported: April 21, 2021 Initiated: March 26, 2021 #D-0332-2021

Product Description

Cefprozil for Oral Suspension USP, 250mg/5mL, packaged as a) 50 mL (when mixed) bottles (NDC 68180-402-01); b) 75 mL (when mixed) bottles (NDC 68180-402-02); and c) 100 mL (when mixed) bottles (NDC 68180-402-03); Rx only, Manufactured for: Lupin Pharmaceutical, Inc., Baltimore, MD 21202; Manufactured by: Lupin Limited, Mandideep 462 046, India.

Reason for Recall

Superpotent Drug

Details

Units Affected
a) 6,816 bottles; b) 3,960 bottles and c) 7,038 bottles
Distribution
Nationwide in the USA and Puerto Rico
Location
Baltimore, MD

Frequently Asked Questions

What product was recalled?
Cefprozil for Oral Suspension USP, 250mg/5mL, packaged as a) 50 mL (when mixed) bottles (NDC 68180-402-01); b) 75 mL (when mixed) bottles (NDC 68180-402-02); and c) 100 mL (when mixed) bottles (NDC 68180-402-03); Rx only, Manufactured for: Lupin Pharmaceutical, Inc., Baltimore, MD 21202; Manufactured by: Lupin Limited, Mandideep 462 046, India.. Recalled by Lupin Pharmaceuticals Inc.. Units affected: a) 6,816 bottles; b) 3,960 bottles and c) 7,038 bottles.
Why was this product recalled?
Superpotent Drug
Which agency issued this recall?
This recall was issued by the FDA Drug on April 21, 2021. Severity: Moderate. Recall number: D-0332-2021.